Lipocine (LPCN) EBITDA Margin (2018 - 2025)

Lipocine's (LPCN) quarterly EBITDA Margin came in at 2933.51% in Q3 2025, down 659.93% on a QoQ basis from 386.03% in Q2 2025.

Lipocine (LPCN) EBITDA Margin (2018 - 2025) Analysis & Trends

Lipocine (LPCN) has 7 years of EBITDA Margin data on file, last reported at 2933.51% in Q3 2025.

Quarterly EBITDA Margin changed N/A year-over-year to 2933.51% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 145.98% (down 7530.0% YoY) and the FY2024 annual result came in at 10.31%, up 61866.0% from the prior year.
EBITDA Margin slipped to 2933.51% in Q3 2025, from 386.03% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 1199.58% in Q4 2023 to a low of 7889.86% in Q1 2023.
A 5-year average of 1925.23% and a median of 545.77% in 2025 frame the typical range for EBITDA Margin.
Annual changes were most pronounced in 2024 — EBITDA Margin surged 793216 bps — and 2025, when it plunged 226913 bps.
Tracing LPCN's EBITDA Margin over 5 years: stood at 79.47% in 2021, then tumbled by 988 bps to 705.51% in 2022, then soared by 270 bps to 1199.58% in 2023, then plunged by 96 bps to 44.27% in 2024, then plunged by 6727 bps to 2933.51% in 2025.
The last three EBITDA Margin figures came in at 2933.51% (Q3 2025), 386.03% (Q2 2025), and 2226.82% (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn	32.54%
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn	17.93%
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn	-0.36%
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn	-35.57%
9	Royalty Pharma	27.12 Bn	26.28 Bn	-	19.75%
10	Lipocine	11.42 Mn	-12.49 Mn	-	-

Download Data